Jeffrey S. Miller, MD | Authors


Adaptive NK Cell Platform Shows Safety for Hematological Malignancies

June 11, 2022

Jeffrey S. Miller, MD, discusses the findings of a study of the Tri-Specific Killer Engager platform for the activation of natural killer cells for the treatment of refractory acute myeloid leukemia and other cancers.